Dogwood Therapeutics, Inc. (DWTX) - Dilution Analysis

10-Q filing | 33.5M shares outstanding

10-K filing | 33.4M shares outstanding

S-3 filing: This prospectus relates to the resale of up to 6,433,126 shares of Common Stock of Dogwood Therapeutics, Inc. by the selling stockholders identified in this prospectus.

8-K filing: Dogwood Therapeutics, Inc. executed a registered direct offering and concurrent private placement with a single institutional investor, involving the sale of common stock, pre-funded warrants, and common stock warrants.

10-Q filing | 2.3M shares outstanding

S-3 filing: This prospectus relates to the resale of up to 28,038,689 shares of Common Stock, par value $0.0001, of Dogwood Therapeutics, Inc., that may be sold from time to time by the selling stockholders named in this prospectus.

8-K filing: Dogwood Therapeutics, Inc. issued 191,017 shares of its common stock to Serpin Pharma Inc. and 191,017 shares of its common stock to Rejuvenation Labs, Inc. in connection with an Exclusive Licensing Agreement.

S-3 filing: The company is filing an S-3 to register an indeterminate number of shares of common stock and preferred stock, an indeterminate principal amount of debt securities, an indeterminate number of warrants, rights to purchase common stock, preferred stock or debt securities, and such indeterminate number of units, as shall have an aggregate initial offering price not to exceed $150,000,000.

10-Q filing | 1.9M shares outstanding

10-K filing | 1.9M shares outstanding

8-K filing: Dogwood Therapeutics, Inc. sold 578,950 shares of its common stock at a price of $8.26 per share in a registered direct offering, resulting in gross proceeds of approximately $4.8 million, which closed on March 14, 2025. ($4.8M proceeds)

8-K filing: Dogwood Therapeutics entered into a Debt Exchange and Cancellation Agreement with Conjoint Inc., exchanging debt for Series A-1 Preferred Stock convertible into Common Stock; also, the company is considering a reverse stock split to maintain Nasdaq compliance. ($19.93M proceeds)

10-Q filing | 1.3M shares outstanding

8-K filing: Virios Therapeutics, Inc. acquired Pharmagesic in exchange for common stock and Series A Preferred Stock, and implemented a reverse stock split effective October 9, 2024, resulting in 1,332,268 shares of Common Stock issued and outstanding.

10-Q filing | 27.8M shares outstanding

8-K filing: Virios Therapeutics, Inc. entered into a placement agency agreement with Maxim Group LLC for a public offering of 8,500,000 shares of common stock at $0.20 per share, with the closing expected on or about May 22, 2024. ($1.7M proceeds)

10-Q filing | 19.3M shares outstanding

10-K filing | 18.8M shares outstanding

10-Q filing | 19.1M shares outstanding

10-Q filing | 18.4M shares outstanding

10-Q filing | 18.3M shares outstanding

10-K filing | 8.3M shares outstanding

10-Q filing | 18.3M shares outstanding

8-K filing: Virios Therapeutics, Inc. entered into an underwriting agreement with ThinkEquity LLC for a public offering of 10,000,000 shares of common stock at $0.50 per share, with an over-allotment option of 1,500,000 shares and warrants to purchase up to 5% of the shares. ($5.0M proceeds)

10-Q filing | 8.3M shares outstanding

10-Q filing | 8.3M shares outstanding

S-3 filing: The company is filing an S-3 to register an indeterminate number of shares of common stock and preferred stock, an indeterminate depositary shares representing preferred stock, an indeterminate principal amount of debt securities, and an indeterminate number of warrants to purchase common stock, preferred stock and/or debt securities as may be offered by the Registrant from time to time, which together shall have an aggregate initial offering price not to exceed $150,000,000.

10-K filing | 8.3M shares outstanding

10-Q filing | 8.3M shares outstanding

10-Q filing | 8.3M shares outstanding

10-Q filing | 8.3M shares outstanding

S-1/A filing: This is a firm commitment initial public offering of 3,000,000 shares of our common stock.

S-1/A filing: This is a firm commitment initial public offering of 3,000,000 shares of our common stock.

S-1/A filing: This is an S-1/A filing providing information on expenses related to the issuance and distribution of securities, indemnification of directors and officers, and recent sales of unregistered securities.

S-1/A filing: This is a firm commitment initial public offering of 3,000,000 shares of our common stock.

S-1/A filing: Virios Therapeutics, Inc. is offering 3,000,000 shares of common stock in a firm commitment initial public offering, with an anticipated initial public offering price between $9.00 and $11.00 per share.

S-1/A filing: This is a firm commitment initial public offering of 3,000,000 shares of our common stock. We anticipate that the initial public offering price of our shares will be between $9.00 and $11.00 and for calculation purposes herein, we assume a mid-point of $10.00 per share.

S-1/A filing: This is a firm commitment initial public offering of shares of common stock. The company intends to use the net proceeds of this offering to advance the preclinical and clinical development of IMC-1 and for working capital and general corporate purposes.

S-1 filing: Virios Therapeutics, Inc. is conducting a firm commitment initial public offering of common stock, with the intention to list on the Nasdaq Capital Market under the symbol "VIRI."